Ashok Seshadri

2 papers in the library · 50 citations · publishing 2024

Papers

Sort Most recent Most cited

Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: A systematic review and meta-analysis.

Journal of Affective Disorders July 1, 2024 Ashok Seshadri, Larry J. Prokop, Balwinder Singh 50 citations

Intravenous (IV) racemic ketamine and intranasal (IN) esketamine have demonstrated rapid antidepressant effects in treatment-resistant depression (TRD). This systematic review aims to evaluate the efficacy and safety of ketamine and esketamine at various dosages for depression. We included randomized controlled trials (RCTs) with parallel group dose comparison of ketamine and esketamine for...

DOI: 10.1016/j.jad.2024.03.137 Full text Major depressive disorder Clinical trials Dose escalation Intranasal esketamine +5

Metabolomic biomarkers for (R, S)‐ketamine and (S)‐ketamine in treatment‐resistant depression and healthy controls: A systematic review

Bipolar Disorders June 1, 2024 Rakesh Kumar, Nicolas A. Nunez, Neha Joshi et al.

AbstractBackgroundKetamine is increasingly used for treatment‐resistant depression (TRD) while its mechanism of action is still being investigated. In this systematic review, we appraise the current evidence of metabolomic biomarkers for racemic ketamine and esketamine in patients with TRD and healthy controls (HCs).MethodsA comprehensive search of several databases (Ovid MEDLINE®, Embase, and...

DOI: 10.1111/bdi.13412